Ultraminiaturized Cell-Based Assays


Overview

Euveda Biosciences has developed an innovative microfluidics-based platform that allows a very wide range of cell-based assays to be performed in an ultraminiaturized format. Specifically, we can enable most cell-based assays typically performed in academic or pharmaceutical research labs to be implemented in an assay volume of ~40nL, which is ~150 times smaller than assays performed in 1536-well plates. The drastic reduction in assay volume directly results in dramatically lower usage of precious cells. Consequently, Euveda's technology allows high-throughput screening or characterization to be performed on cell types that are difficult or expensive to grow or obtain in large numbers, such as primary cells and stem cells. Usage of expensive biochemical reagents is likewise decreased, leading to tremendous cost savings.

Importantly, fluid handling is directly integrated into Euveda's assay technology. This has three significant advantages. First, it avoids the need for expensive fluid handling equipment typically associated with sub-microliter scale assays. Second, fluid dispensing can be done more accurately than with pipetting or acoustic methods. Third, fluid exchange can be performed in a highly controlled and gentle manner, enabling the use of complex multi-step, multi-wash protocols to be performed at high miniaturization levels (whereas currently assays performed at the 384- or 1536-well level are restricted to a handful of steps and zero to a few washes).


Product Preview

Euveda is currently testing prototypes of a microfluidic device with 96-well throughput, and a companion control box (with USB interface) that can be easily operated in a "one-click" fashion by untrained laboratory staff. Cell culture, stimulation, and response monitoring can all be performed within the device. To facilitate drug screening applications, this device is designed to allow drug libraries to be manually introduced using a multi-channel pipettor or robotically by the liquid handling machine of your choice. The device will likewise be compatible with imaging systems already available at many facilities.

Some of the many assays that can be performed on primary cells or cell lines in this device are:

  1. Drug screening studies: Our initial product is primarily targeted for secondary and tertiary stage drug screening studies. It can be used for screening using small-molecule drug libraries, biologics libraries, siRNA libraries, etc. Novel dosage profiles such as multiple periodic doses of a drug can also be achieved.
  2. Time course studies: Cellular responses can be sampled at pre-defined time points that can be spaced non-linearly, thus allowing the observation of fast early responses and slow late responses within the same experiment.
  3. Live cell imaging: Cell responses can be monitored in real time using phase contrast or fluorescence imaging.
  4. Fluorescence-based readouts: The device is compatible with cellular probes that fluoresce in the UV or visible light wavelengths. Introduction and incubation of the probes and other reagents (e.g. fixatives, permeabilization agents, antibodies, etc.) can be completely automated in the device, without any external input required.

Partnership Opportunities

Euveda is currently performing pilot testing projects with a select group of academic labs and drug screening centers, but is willing to consider collaborative proposals from other academic or industry groups who are interested in early access to our products. Interested parties can contact Euveda at mail@euvedabiosciences.com to discuss potential collaborations or to receive product updates and launch announcements.